Discover trends, market shifts, and competitive outlooks for the bevacizumab biosimilars industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

#How Has the Bevacizumab Biosimilars Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, the market for bevacizumab biosimilars has exhibited impressive growth. It’s slated to increase from a remarkable $1.53 billion in 2024 to an estimated $1.66 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.2%. The upward trend in the historic period can be linked to several factors including expiration of patents, control of healthcare costs, rising rates of cancer, strong competition in the market, patient access and affordability, and the acceptance of biosimilars.

The market for bevacizumab biosimilars is predicted to experience substantial expansion in the upcoming years, escalating to a value of $2.27 billion in 2029 with a Compound Annual Growth Rate (CAGR) of 8.1%. The anticipated growth during this forecast period can be credited to factors such as the increasing demand for cancer treatments, expertise in biosimilar development, pressure on healthcare systems, and the regulatory environment for biosimilars, along with biosimilar interchangeability. Key trends identified for this forecast period encompass collaborations and partnerships, advancements and approvals in regulation, innovation in biosimilar development, strategies for market access, and biosimilar lifecycle management.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

What Are the Primary Drivers Supporting the Market Growth of the Bevacizumab Biosimilars Market?

The bevacizumab biosimilar market is projected to expand owing to the increasing incidence of cancer. The term ‘cancer incidence’ denotes the count of new cancer instances in a definite populace during a specific period. Bevacizumab is a biological agent that blocks the formation of new blood vessels in tumors, potentially causing shrinkage and stunted growth of the tumor. It is considered equivalent to reference biologics in effectiveness and safety when used to treat patients with advanced non-small cell lung cancer or metastatic colorectal cancer. To illustrate, in October 2024, 346,217 fresh cancer cases were reported by the UK’s National Health Service (NHS), averaging 948 new cases daily, marking a 5% increase from the 329,664 diagnoses in 2021. Additionally, cancer diagnoses have seen a 7% surge, moving from 167,917 to 180,877 in 2022. This rising cancer prevalence thus fuels the growth of the bevacizumab biosimilars market.

Which Primary Segments of the Bevacizumab Biosimilars Market Are Driving Growth and Industry Transformations?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of the Bevacizumab Biosimilars Market?# Market?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Most Significant Market Trends in the Bevacizumab Biosimilars Market?

The trend of product innovation is increasingly becoming popular in the bevacizumab biosimilars market. Key market leaders are heavily focusing on developing innovative products to bolster their market standing. For example, in May 2022, pharmaceutical firms Viatris and Biocon Biologics, both based in the US, introduced a biosimilar named Abevmy (bevacizumab), similar to Roche’s Avastin (bevacizumab). Abevmy has been given the green light by Health Canada for its use in four different oncology indications. The product guarantees effectiveness, safety, and quality similar to the reference biologic since it is a humanized monoclonal antibody (MA) that attaches to and impedes the biologic function of human vascular endothelial growth factor (VEGF).

View the full report here:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

What Parameters Are Used to Define the Bevacizumab Biosimilars Market?

Bevacizumab biosimilars are a type of medication that is highly similar to a reference biologic drug called bevacizumab. It is commonly used to inhibit the growth of new blood vessels in tumors, thereby slowing down their progression.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10848

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model